title: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
abstract: We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years, with a median follow-up time of 10 years. Clinical event information was updated in all living patients (with the exception of 3 patients) in 2009. Survival end points were improved in patients treated with R-CHOP: the 10-year progression-free survival was 36.5%, compared with 20% with CHOP alone, and the 10-year overall survival was 43.5% compared with 27.6%. The same risk of death due to other diseases, secondary cancers, and late relapses was observed in both study arms. Relapses occurring after 5 years represented 7% of all disease progressions. The results from the 10-year analysis confirm the benefits and tolerability of the addition of rituximab to CHOP. Our findings underscore the need to treat elderly patients as young patients, with the use of curative chemotherapy.
authors.affiliation: Hospices Civils de Lyon and Université Lyon-1, Lyon, France. bertrand.coiffier@chu-lyon.fr
authors.forename: Bertrand
authors.initials: B
authors.lastname: Coiffier
authors.forename: Catherine
authors.initials: C
authors.lastname: Thieblemont
authors.forename: Eric
authors.initials: E
authors.lastname: Van Den Neste
authors.forename: Gérard
authors.initials: G
authors.lastname: Lepeu
authors.forename: Isabelle
authors.initials: I
authors.lastname: Plantier
authors.forename: Sylvie
authors.initials: S
authors.lastname: Castaigne
authors.forename: Sophie
authors.initials: S
authors.lastname: Lefort
authors.forename: Gérald
authors.initials: G
authors.lastname: Marit
authors.forename: Margaret
authors.initials: M
authors.lastname: Macro
authors.forename: Catherine
authors.initials: C
authors.lastname: Sebban
authors.forename: Karim
authors.initials: K
authors.lastname: Belhadj
authors.forename: Dominique
authors.initials: D
authors.lastname: Bordessoule
authors.forename: Christophe
authors.initials: C
authors.lastname: Fermé
authors.forename: Hervé
authors.initials: H
authors.lastname: Tilly
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000633:toxicity; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002423:Cause of Death; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone